Skip to main content

Emerging Medical Technologies

This website provides licensing guidance for emerging medical technologies. The licensing guidance consists of general licensing considerations, specific radiation safety aspects of the emerging medical technology, and training and experience expectations for those authorized to use the emerging medical technology. This website may also help stakeholders who are developing new methods and technologies that may one day be used to treat medical patients. It also contains a record of the emerging medical technologies whose use has been evaluated for licensing by the NRC. Contact Us to submit medical-related inquiries.

On this page:

Rulemaking: NRC Regulation of Emerging Medical Technologies

Title 10 of the Code of Federal Regulations Part 35, Subpart K – Other Medical Uses of Byproduct Material or Radiation From Byproduct Material (10 CFR 35.1000) describes the process to obtain a license, or an amendment to a license, for a new medical use of byproduct material or radiation from byproduct material, which is not addressed in other parts of 10 CFR Part 35 (i.e., an emerging medical technology). Additional requirements are included in 10 CFR 35.12(d), "Application for license, amendment, or renewal."

In the Staff Requirements Memorandum (SRM) for SECY-21-0013, “Rulemaking Plan to Establish Requirements for Rubidium-82 Generators and Emerging Medical Technologies,” the Commission approved the initiation of a rulemaking that would address rubidium-82 generators along with all current, well-established emerging medical technologies, plus create added flexibility throughout 10 CFR Part 35 to accommodate future emerging medical technologies. The NRC’s rulemaking plan is publicly available. In addition, in the SRM for SECY-20-0005, “Rulemaking Plan for Training and Experience Requirements for Unsealed Byproduct Material (10 CFR Part 35),” the Commission directed the staff to re-evaluate and gather stakeholder feedback on all aspects pertaining to the training and experience requirements for use of emerging medical technologies.

Rulemaking Schedule and Public Involvement

Schedule and Public Involvement MilestonesDateRelated Documents
NRC staff develops SECY-21-0013 to request Commission approval to initiate a rulemaking to address calibration and dosage measurement for rubidium-82 generators and establish performance-based requirements for emerging medical technologies.February 9, 2021SECY-21-0013
Commission issues staff requirements memorandum (SRM) SRM-SECY-21-0013January 13, 2022SRM-SECY-21-0013
NRC staff publishes for public comment the Regulatory Basis for “Rubidium-82 Generators, Emerging Technologies, and Other Medical Use of Byproduct Material.”July 3, 2023

Regulatory Basis Document

FRN

NRC holds public meeting on Regulatory Basis DocumentAugust 29, 2023

Meeting summary

Meeting transcript

NRC staff presentation

End of public comment period on Regulatory Basis DocumentDecember 15, 2023 
Workshop on Proposed RuleTBD 2024 
NRC staff submits Proposed Rule to CommissionWinter 2026 
NRC publishes Proposed Rule and draft Implementation Guidance for public commentTBD 
Public engagement on Proposed Rule and Implementation GuidanceTBD 
NRC staff submits Final Rule to CommissionTBD 
NRC publishes Final Rule and Implementation GuidanceTBD 

More information about the NRC’s rulemaking process can be found in the NRC’s Rulemaking page. The NRC will use the Medical List Server e-mail to provide updates on the rubidium-82 generators and emerging medical technologies rulemaking as they become available.

To top of page

NRC Review of Emerging Medical Technologies

In 2020, the NRC instituted a streamlined process for the reviews of emerging medical technologies. The NRC established a Standing Committee composed of NRC and Agreement State staff, to help facilitate early feedback regarding reviews of emerging medical technologies and licensing guidance development. The charter and State Agreement procedure for the Standing Committee for Reviewing Emerging Medical Technologies (SCREMT) are publicly available. The SCREMT meets on an as needed basis to provide feedback on licensing determination for emerging medical technologies, as well as to review and comment on draft licensing guidance documents developed by the NRC.

To top of page

Manufactures: Have a New Medical Use and Looking to get Started?

If you are a manufacturer or early user of a new medical use, see these frequently asked questions and answers for emerging medical technology (EMT) licensing. Frequently Asked Questions For Licensing of Emerging Medical Technologies.

To top of page

Status of NRC Review of Emerging Technologies

Below is an Emerging Technologies Table: a current list of emerging technologies, status, and links to corresponding documents.

Note: New entries will be added as additional emerging technologies are identified. Licensing guidance will be updated when necessary to address comments from stakeholders. To submit comments on or inquire about a specific licensing guidance document, contact the individual listed in that document or contact us using our electronic form. If applicable, you can also contact the appropriate NRC Regional Office or Agreement State for assistance.

This page includes links to files in non-HTML format. See Plugins, Viewers, and Other Tools for more information.

Emerging Technologies
Technology NameStatusDocument
Date
Document(s)
Akesis Galaxy RTiLicensed under 35.1000August 2024Licensing Guidance
Alpha Tau Alpha DaRTTM Manual BrachytherapyLicensed Under 35.1000February 2025Licensing Guidance
(Revision 1)
 
Supersedes:
March 2022

Consolidated Technical Analysis
Best Vascular, Inc. Beta-Cath Intravascular Brachytherapy (IVB) SystemLicensed under 35.1000August 2006Licensing Guidance
CivaDermTM Superficial Manual Brachytherapy DeviceLicensed under 35.400July 2023MEMO: Licensing Guidance for Superficial Manual Brachytherapy CivaDerm Device
Eye90 microspheresLicensed Under 35.1000September 2024Licensing Guidance
Germanium-68/Gallium-68 Pharmaceutical Grade Generator (IRE Galli Eo, Eckert & Ziegler)Licensed under 35.1000July 2019Licensing Guidance
GT Medical Technologies GammatileLicensed under 10 CFR 35.400August 2019MEMO: Licensing for Medical Technologies Gammatile
I-125 Iotrex Liquid Brachytherapy Source in Cytyc GliaSite Radiation Therapy SystemmLicensed under 35.1000August 2006Licensing Guidance
Leksell Gamma Knife® Perfection, Icon, and Elekta EspritLicensed under 35.1000May 2023Licensing Guidance

Supersedes:
January 2019
May 2016
July 2007 (Perfexion only)
Low Activity Radioactive Seeds Used for Localization of Non-Palpable Lesions and Lymph Nodes Licensing GuidanceLicensed under 35.1000October 2016Licensing Guidance

Supersedes:
Sept 2006
Lutetium-177 Radiopharmaceuticals (Lutathera®, PluvictoTM)Licensed under 35.300December 2022MEMO: Licensing of Lutetitum-177 (revised)

Supersedes:
June 2018
LV Liberty Vision Yttrium-90 Disc and iWand® Ophthalmic SystemLicensed under 35.1000June 2025Licensing Guidance

Consolidated Technical Analysis
NeoVista, Inc's Epi-Rad90 (Sr-90) Ophthalmic SystemLicensed under 35.1000April 2009Licensing Guidance
NorthStar Medical Radioisotopes, LLC RadioGenix™ Molybdenum-99/Technetium-99m Generator System Licensing Guidance for Medical Use Licensees, Medical Use Permittees, and Commercial Nuclear PharmaciesLicensed under 35.1000 and 10 CFR 30.33December 2021Licensing Guidance

(Revision 2)

Supersedes the Temporary Addendum and Revision 1
May 2021Temporary COVID-19 Addendum
January 2020

Licensing Guidance
(Revision 1)

Supersedes:
Feb 2018

Nucletron seedSelectron® System, Isotron Brachytherapy Sources and Nucletron FIRST™ SystemRetractedN/AN/A
Radium-223 DichlorideLicensed under 35.300January 2013MEMO: Licensing for Ra-223 Dichloride
RefleXion Medical Radiotherapy SystemLicensed under 10 CFR 35.200 for localizationApril 2025MEMO: Licensing for RefleXion Medical Radiotherapy System
Technegas® Aerosol and Technegas Plus SystemLicensed under 35.200January 2024MEMO: Licensing for Technegas Aerosol and Technegas Plus System
TheraSphere and SIRSpheres Yttrium-90 MicrospheresLicensed under 35.1000April 2021Licensing Guidance
(Revision 10.2)

Supersedes:
March 2020
November 2019
February 2016
June 2012
Oct 2011
Jan 2011
Sept 2008
Aug 2008
Dec 2007
Sept 2007
Jan 2004
Oct 2002
Thorium GeneratorsLicensed as  byproduct materialApril 2025MEMO: Licensing of Thorium Generators
ViewRay System for Radiation TherapyLicensed under 35.1000July 2013Licensing Guidance
Xcision® GammaPod™Licensed under 35.1000January 2020Licensing Guidance

To top of page

Page Last Reviewed/Updated Thursday, August 13, 2026

Page Last Reviewed/Updated Thursday, August 13, 2026